Search results
Good distribution practice (GDP) describes the minimum standards that a wholesale distributor must meet to ensure that the quality and integrity of medicines is maintained throughout the supply chain.
- Guidelines of 5 November 2013 on Good Distribution Practice of ...
Today’s distribution network for medicinal products is...
- Guidance on good manufacturing practice and good distribution practice ...
The European Medicines Agency's (EMA) provides answers to...
- Good Manufacturing and Distribution Practices
Good Distribution Practice (GDP) The wholesale distribution...
- Commission Guidelines on Good Distribution Practice of Medicinal ...
All distribution activities should be clearly defined and...
- Guidelines of 5 November 2013 on Good Distribution Practice of ...
Today’s distribution network for medicinal products is increasingly complex and involves many players. These Guidelines lay down appropriate tools to assist wholesale distributors in conducting their activities and to prevent falsified medicines from entering the legal supply chain. Compliance with these Guidelines will ensure control of the
The European Medicines Agency's (EMA) provides answers to frequently asked questions on good manufacturing practice (GMP) and good distribution practice (GDP), as discussed and agreed by the GMP/GDP Inspectors Working Group.
The wholesale distribution of medicinal products is an important activity in integrated supply chain management. Today’s distribution network for medicinal products is increasingly complex and involves many players. These guidelines lay down appropriate tools to assist wholesale distributors in conducting their activities and to prevent falsified
Distribution is an important activity in the integrated supply-chain management of pharmaceutical products. Various people and entities are generally responsible for the handling, storage and distribution of such products.
Good Distribution Practice (GDP) The wholesale distribution of medicinal products and active substances is an important activity. The quality and the integrity of medicinal products can be affected by a lack of adequate control.
All distribution activities should be clearly defined and systematically reviewed and all critical steps of distribution processes and significant changes should be validated. The quality system should incorporate quality risk management principles.
